Patients treated with platinum-based chemotherapy drugs have the probability of developing PSVD. The diagnosis of PSVD depends on liver biopsy. In addition, the level of portal vein pressure has guiding value in the diagnosis and prognosis of PSVD. Many studies have shown that liver and spleen stiffness have high accuracy in diagnosis and prognosis. The purpose of this study is to evaluate the efficacy of the combination of liver and spleen stiffness in the diagnosis of PSVD and to search for effective biomarkers for the diagnosis of PSVD through a single-center, prospective, observational study.
PSVD is a supplement to non-cirrhotic portal hypertension and is defined as a class of diseases with characteristic pathological changes based on portal vein or hepatic sinuses abnormalities without cirrhosis. Some patients treated with platinum-based chemotherapy drugs will develop PSVD, which is clinically manifested as portal hypertension related complications. The diagnosis of PSVD depends on liver biopsy. In addition, the level of portal vein pressure has guiding value in the diagnosis and prognosis of PSVD. However, liver biopsy and pressure measurement are invasive methods. Many studies have shown that liver and spleen stiffness have high accuracy in diagnosis and prognosis. The purpose of this study is to evaluate the efficacy of the combination of liver and spleen stiffness in the diagnosis of PSVD and to search for effective biomarkers for the diagnosis of PSVD through a single-center, prospective, observational study.
Study Type
OBSERVATIONAL
Enrollment
1,000
liver and spleen stiffness measurement are non-invasive tools for evaluation of cirrhosis and portal hypertension
Nanfang hospital, Southern Medical Uiversity
Guangzhou, Guangdong, China
RECRUITINGSearching for valid non-invasive tools for the diagnosis of PSVD
The sensitivity and specificity of the non-invasive models for the diagnosis of PSVD reached 85% and 60%, respectively
Time frame: 2 years
Patients developed portal-hypertension-related complications
clinically significant ascites, esophagogastric variceal hemorrhage, hepatic encephalopathy, etc.
Time frame: 3 years
Patients died
All-cause death
Time frame: 3 years
Patients underwent liver transplantation
Patients underwent liver transplantation during follow up
Time frame: 3 years
Patients reached the final follow-up time
Patients had accepted 3-year follow up
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.